A new motif in the n-terminal of acetylcholinesterase triggers amyloid-β aggregation and deposition

CNS Neuroscience and Therapeutics

Volumn 20, Issue 1, 2014, Pages 59-66

  Hou, Li Na ^a   Xu, Jian Rong ^a   Zhao, Qing Nan ^a   Gao, Xiao Ling ^a   Cui, Yong Yao ^a   Xu, Jun ^b   Wang, Hao ^a   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Amyloid ; Oligomer

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; THIOFLAVINE;

ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DOT HYBRIDIZATION; FLUORESCENCE ANALYSIS; HUMAN; PROTEIN AGGREGATION; PROTEIN MOTIF; PROTEIN STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY;

ACETYLCHOLINESTERASE; ALZHEIMER'S DISEASE; AMYLOID-Β; OLIGOMER;

ACETYLCHOLINESTERASE; AMINO ACID MOTIFS; AMYLOID BETA-PEPTIDES; CIRCULAR DICHROISM; FLUOROMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNOBLOTTING; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; PLAQUE, AMYLOID; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890556839     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12161     Document Type: Article

References (36)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-2117.
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
3. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314:777-781.
4. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-639.
5. Muñoz FJ, Inestrosa NC. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett 1999;450:205-209.
6. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84.
7. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010;16:235-245.
8. Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opin Investig Drugs 2011;20:1243-1261.
9. Morán MA, Mufson EJ, Gómez-Ramos P. Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 1993;85:362-369.
10. Ulrich J, Meier-Ruge W, Probst A, Meier E, Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol 1990;80:624-628.
11. Luo W, Li YP, He Y, et al. Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents. Eur J Med Chem 2011;46:2609-2616.
12. Reyes AE, Chacón MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol 2004;164:2163-2174.
13. Nakamura S, Kawashima S, Nakano S, Tsuji T, Araki W. Subcellular distribution of acetylcholinesterase in Alzheimer's disease: abnormal localization and solubilization. J Neural Transm Suppl 1990;30:13-23.
14. Rees TM, Berson A, Sklan EH, et al. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res 2005;2:291-300.
15. Reyes AE, Perez DR, Alvarez A, et al. A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem Biophys Res Commun 1997;232:652-655.
16. Xie Q, Wang H, Xia Z, et al. Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem 2008;51:2027-2036.
17. Kisilevsky R, Fraser PE. A beta amyloidogenesis: unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol 1997;32:361-404.
18. Hoyer W, Grönwall C, Jonsson A, et al. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc Natl Acad Sci USA 2008;105:5099-5104.
19. Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc 2006;1:2406-2415.
20. Carletti E, Colletier JP, Dupeux F, Trovaslet M, Masson P, Nachon F. Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation. J Med Chem 2010;53:4002-4008.
21. Yoshiike Y, Minai R, Matsuo Y, Chen YR, Kimura T, Takashima A. Amyloid oligomer conformation in a group of natively folded proteins. PLoS ONE 2008;3:e3235.
22. Wang M, Jiji RD. Spectroscopic detection of β -sheet structure in nascent Aβ oligomers. J Biophotonics 2011;4:637-644.
23. Fezoui Y, Teplow DB. Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem 2002;277:36948-36954.
24. Doi Y, Mizuno T, Maki Y, et al. Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid β Neurotoxicity in in Vitro and in Vivo Models of Alzheimer's Disease. Am J Pathol 2009;175:2121-2132.
25. Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881-891.
26. Fernandez HL, Moreno RD, Inestrosa NC. Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. J Neurochem 1996;66:1335-1346.
27. Fernàndez-Busquets X, Ponce J, Bravo R, et al. Modulation of amyloid beta peptide(1-42) cytotoxicity and aggregation in vitro by glucose and chondroitin sulfate. Curr Alzheimer Res 2010;7:428-438.
28. Ma B, Nussinov R. Stabilities and conformations of Alzheimer's beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): sequence effects. Proc Natl Acad Sci USA 2002;99:14126-14131.
29. Carrell RW, Lomas DA. Conformational disease. Lancet 1997;350:134-138.
30. Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993;90:9031-9035.
31. Sanson B, Colletier JP, Xu Y, et al. Backdoor opening mechanism in acetylcholinesterase based on X-ray crystallography and molecular dynamics simulations. Protein Sci 2011;20:1114-1118.
32. Cheung J, Rudolph MJ, Burshteyn F, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282-10286.
33. Cottingham MG, Hollinshead MS, Vaux DJ. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry 2002;41:13539-13547.
34. Cottingham MG, Voskuil JL, Vaux DJ. The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry 2003;42:10863-10873.
35. Collins FS, Drumm ML, Cole JL, Lockwood WK, Vande Woude GF, Iannuzzi MC. Construction of a general human chromosome jumping library, with application to cystic fibrosis. Science 1987;235:1046-1049.
36. Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, et al. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging 2012;33:2641-2660.